Simulations Plus, Inc. · NASDAQ:SLP

Simulations Plus — Technical Presentation (March 2024)

40 slides from Simulations Plus's technical presentation, Mar 20, 2024

  1. Slide 1: Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond

    Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond March 20, 2024 1 NASDAQ: SLP

  2. Slide 2: Outline

    Outline Proof PBPK Works for FIH PK Predictions Regulatory Perspective Breaking Down the Components of a PBPK Model Uncertainty and Sensitivity Model Applications 2 NASDAQ: SLP

  3. Slide 3: Considerations

    Considerations Use everything that you know, but keep the model as simple as possible  Aim to use PBPK not empirical modelling  Combine compound specific data with physiology as they are intimately interconnected and explicable only by reference to the whole Preclinical verification can increase t

  4. Slide 4: Considerations

    Considerations Always include uncertainty  Never give single point estimates Be realistic with your expectations  A successful prediction gets the category right or within 2-fold, but not necessarily matching values exactly Sensitivity analysis and model application can inform future decisions  A

  5. Slide 5: Proof PBPK Works for FIH PK Predictions

    Proof PBPK Works for FIH PK Predictions “In the majority of cases, PBPK gave more accurate predictions of pharmacokinetic parameters and plasma concentration-time profiles than the Dedrick approach.” “This evaluation demonstrates that PBPK models can lead to reasonable predictions of human pharmacok

  6. Slide 6: Proof PBPK Works for FIH PK Predictions

    Proof PBPK Works for FIH PK Predictions “The simulation results using PBPK were shown to be superior to those obtained via traditional one compartment analyses. In many cases, this difference was statistically significant.” “Our prospective human PK prediction methods yielded good prediction results

  7. Slide 7: Regulatory Guidance for PBPK Modelling

    Regulatory Guidance for PBPK Modelling “Primarily for drug developers, FIH “PBPK modelling is a state-of-the-art modelling tool for assessing an prediction using PBPK is important for appropriate starting dose for healthy volunteers.[…] The methods used decision-making and allows additional and calc

  8. Slide 8: An Industry Defined FIH PBPK Strategy

    An Industry Defined FIH PBPK Strategy Flow diagrams for each essential component of a FIH prediction using PBPK modelling 8 NASDAQ: SLP

  9. Slide 9: Use Everything You Know

    Use Everything You Know FIH Simulator includes the major preclinical species to enable you to move seamlessly from mouse, rat, dog, minipig, rabbit, cyno through to human in one platform – The overall risk profile can be assessed in ADMET Predictor – Inputs without measured data can be predicted usi

  10. Slide 10: Use Everything You Know: Start with QSPR + PBPK

    Use Everything You Know: Start with QSPR + PBPK BDDCS – Biopharmaceutics Drug Disposition Classification System ECCS – Extended Clearance Classification System QSPR – Quantitative Structure-Property Relationship BCS – Biopharmaceutic Classification System 10 NASDAQ: SLP

  11. Slide 11: Use Everything You Know: Compound Assessment Using QSPR + PBPK

    Use Everything You Know: Compound Assessment Using QSPR + PBPK 11 NASDAQ: SLP

  12. Slide 12: Use Everything You Know: Critical Thinking Using QSPR + PBPK

    Use Everything You Know: Critical Thinking Using QSPR + PBPK Cutoff between low and high permeability is 1.2cm/s x 10^4 based on metoprolol ECCS, S+ Mechanistic Clearance Classification and transporter substrate predictions are in the notes 12 NASDAQ: SLP

  13. Slide 13: Use Everything You Know: Pragmatic Assessment Using QSPR + PBPK

    Use Everything You Know: Pragmatic Assessment Using QSPR + PBPK Blue – Plasma concentration Red – Amount dissolved Cyan – Amount absorbed Multiple options to predict clearance: models for HLM, hepatocytes, enzyme kinetics 13 NASDAQ: SLP

  14. Slide 14: Preclinical Verification to Better Predict Human PK

    Preclinical Verification to Better Predict Human PK Distribution BPR blood/plasma ratio Fup fraction unbound in plasma, Kp tissue-to-plasma partition coefficient, QWBA Quantitative Whole Body Autoradiography, 14 SpecPStc specific in-vivo diffusional clearance per millilitre of tissue cell volume. NA

  15. Slide 15: Preclinical Verification: Assessing the Pieces of the Jigsaw Puzzle

    Preclinical Verification: Assessing the Pieces of the Jigsaw Puzzle FIH prediction for IV dosing of Tobramycin : Distribution Data • Preclinical IV Cp vs Time profiles • Use the Lukacova Kp equation • LogP/D • Input available measured data • pKa • PBPK record per preclinical species • Fraction unbou

  16. Slide 16: Preclinical Verification: Applying Critical Thinking

    Preclinical Verification: Applying Critical Thinking FIH prediction for IV dosing of Tobramycin : Distribution Assess Model • Predicted Vss is too large causing a rapid • No measured RBP, set as 1-haematocrit distribution to tissues and a slow return to • Use a permeability limited tissue model to s

  17. Slide 17: Preclinical Verification: Applying Critical Thinking

    Preclinical Verification: Applying Critical Thinking FIH prediction for IV dosing of Tobramycin : Distribution Species Observed Vss Predicted Vss Pred/Obs Rat 0.093 L 0.190 L 2.0 Dog 12.24 L 16.63 L 1.4 17 NASDAQ: SLP

  18. Slide 18: Verification Defines Strategy for Human Prediction

    Preclinical Verification Defines Strategy for Human Prediction Distribution -Tobramycin 18 NASDAQ: SLP

  19. Slide 19: Preclinical Verification to Better Predict Human PK

    Preclinical Verification to Better Predict Human PK Metabolism and Elimination CLR renal clearance CLR,u unbound renal clearance ECCS Extended Clearance Classification System Fup fraction unbound in plasma GFR glomerular filtration rate 19 NASDAQ: SLP IVIVE in-vitro in-vivo extrapolation.

  20. Slide 20: Verification: Combining Measured Data with Predicted Properties

    Preclinical Verification: Combining Measured Data with Predicted Properties Metabolism and Elimination Data • Renal clearance from IV studies • Observed or in vitro biliary clearance data • Validate CLR prediction • Microsomal, hepatocyte or • Adjust CLR settings in the kidney enzyme kinetic data ti

  21. Slide 21: Verification: Combining Measured Data with Predicted Properties

    Preclinical Verification: Combining Measured Data with Predicted Properties Metabolism and Elimination Data • Renal clearance from IV studies • Microsomal, hepatocyte or enzyme kinetic data • Observed biliary clearance data 21 NASDAQ: SLP

  22. Slide 22: Preclinical Verification to Better Predict Human PK

    Preclinical Verification to Better Predict Human PK Oral Absorption ASF absorption scale factors BSSR bile salt solubilisation ratio MPT mean precipitation time Efflux transporters can be incorporated in GastroPlus models with a simple method (e.g. adjusting permeability based on preclinical observa

  23. Slide 23: Verification: Building on the IV Model

    Preclinical Verification: Building on the IV Model FIH prediction for PO dosing of Cilostazol : Oral Absorption Data • Moderately lipophilic • Set IV model – compartmental distribution • Essentially neutral at physiological pH and NCA CL to enable the oral absorption to • Low to moderate solubility

  24. Slide 24: Verification: Assessing the sensitive parameters

    Preclinical Verification : Assessing the sensitive parameters FIH prediction for PO dosing of Cilostazol : Oral Absorption 24 NASDAQ: SLP

  25. Slide 25: Verification: Additional measured data to enable prediction

    Preclinical Verification : Additional measured data to enable prediction FIH prediction for PO dosing of Cilostazol : Oral Absorption Assess Model • Dissolution is the rate limiting step for • Fit distribution to particle size data absorption • Apply to model • Solubility has been fitted to measured

  26. Slide 26: Verification: Additional measured data to enable prediction

    Preclinical Verification : Additional measured data to enable prediction FIH prediction for PO dosing of Cilostazol : Oral Absorption • Fit distribution to particle size data • Apply to model • Verify with other doses / species / formulations Blue – Plasma concentration Red – Amount dissolved 26 NAS

  27. Slide 27: Verification Defines Strategy for Human Prediction

    Preclinical Verification Defines Strategy for Human Prediction Oral Absorption - Cilostazol 27 NASDAQ: SLP

  28. Slide 28: Preclinical Verification to Better Predict Human PK

    Preclinical Verification to Better Predict Human PK Gut Wall Metabolism CLint hepatic intrinsic clearance Fg fraction of drug escaping gut wall metabolism Km concentration of substrate at half Vmax Vmax maximum velocity or rate of enzyme catalyzed reaction 28 NASDAQ: SLP Gut wall metabolism is often

  29. Slide 29: Verification: Gap Analysis

    Preclinical Verification: Gap Analysis FIH prediction for PO dosing of Cilostazol : Gut Wall Metabolism Data • CYP3A4 is predicted to metabolise • Metabolism data Cilostazol, which is also present in the • Prediction of the human CL gut • Incorporate learnings from preclinical PO • Isoforms involved

  30. Slide 30: Verification: Extrapolation to Human

    Preclinical Verification: Extrapolation to Human FIH prediction for PO dosing of Cilostazol : Gut Wall Metabolism Assess Model • Predicted human CLh is approximately 40% of liver blood flow • Simulated profile using the predicted enzyme kinetics results in a Fh of ~59% • Fg in human is predicted to

  31. Slide 31: Verification Defines Strategy for Human Prediction

    Preclinical Verification Defines Strategy for Human Prediction Gut Wall Metabolism 31 NASDAQ: SLP

  32. Slide 32: Always Include Uncertainty

    Always Include Uncertainty 32 NASDAQ: SLP

  33. Slide 33: Understanding the Sensitive Parameters: Planning for the Future

    Understanding the Sensitive Parameters: Planning for the Future • Will micronisation improve the oral exposure? • If CL or Vss is uncertain, is an IV microdose study recommended? • Will dosing with food improve the duration of action or decrease the oral exposure? • Will further modelling be require

  34. Slide 34: Model Application Beyond FIH: Additional Learning

    Model Application Beyond FIH: Additional Learning • Modelling high dose PK data in preclinical species to enable the prediction of Toxicology dose levels and frequency – To aid in the design of these pivotal supporting studies • Predicting the PK in the target population in addition to healthy volun

  35. Slide 35: Model Application Beyond FIH: Inform Your Clinical Plan

    Model Application Beyond FIH: Inform Your Clinical Plan • Models developed using the FIH Simulator can be used to: – predict the possibility of DDIs with your test compound as the victim or the perpetrator – Consider additional dosage routes • This does require the purchase of additional modules 35

  36. Slide 36: Regulatory Applications

    Regulatory Applications 31 Organizations (innovator & generic companies combined) Fig. 1 Regulatory Applications of GastroPlus® (PBBM/PBPK Modeling) in the Pharmaceutical Industry (Years 2020-2022): Results from Survey 36 NASDAQ: SLP

  37. Slide 37: Considerations

    Considerations • Use everything that you know, but keep the model as simple as possible – Aim to use PBPK not empirical modelling – Combine compound specific data with physiology as they are intimately interconnected and explicable only by reference to the whole • Preclinical verification can increa

  38. Slide 38: References

    References Slide 10 1Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. 2Wu CY, Benet LZ. Predicting drug disposition via applicatio

  39. Slide 39: References

    References Slide 19 1Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV. Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. Drug Metab Dispos. 2017;

  40. Slide 40: Interested in learning more? Contact

    Interested in learning more? Contact: Becky Graves Director, Simulation Studies becky.graves@simulations-plus.com Peter Kilford, Ph.D. Associate Vice President, Software Business Development peter.kilford@simulations-plus.com simulations-plus.com/fih simulations-plus.learnupon.com/store 40 NASDAQ: S

Simulations Plus — Technical Presentation (March 2024) on 6ix